RU2019115913A - Природные комбинированные гормонозаместительные составы и способы терапии - Google Patents

Природные комбинированные гормонозаместительные составы и способы терапии Download PDF

Info

Publication number
RU2019115913A
RU2019115913A RU2019115913A RU2019115913A RU2019115913A RU 2019115913 A RU2019115913 A RU 2019115913A RU 2019115913 A RU2019115913 A RU 2019115913A RU 2019115913 A RU2019115913 A RU 2019115913A RU 2019115913 A RU2019115913 A RU 2019115913A
Authority
RU
Russia
Prior art keywords
moderate
symptoms associated
pharmaceutical composition
estradiol
vasomotor symptoms
Prior art date
Application number
RU2019115913A
Other languages
English (en)
Russian (ru)
Other versions
RU2019115913A3 (cg-RX-API-DMAC10.html
Inventor
Джулия М. АМАДИО
Брайан А. БЕРНИК
Себастьян МИРКИН
Original Assignee
Терапьютиксмд, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Терапьютиксмд, Инк. filed Critical Терапьютиксмд, Инк.
Publication of RU2019115913A publication Critical patent/RU2019115913A/ru
Publication of RU2019115913A3 publication Critical patent/RU2019115913A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2019115913A 2016-12-05 2017-12-05 Природные комбинированные гормонозаместительные составы и способы терапии RU2019115913A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US62/430,339 2016-12-05
US201762481060P 2017-04-03 2017-04-03
US62/481,060 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (2)

Publication Number Publication Date
RU2019115913A true RU2019115913A (ru) 2021-01-15
RU2019115913A3 RU2019115913A3 (cg-RX-API-DMAC10.html) 2021-03-19

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019115913A RU2019115913A (ru) 2016-12-05 2017-12-05 Природные комбинированные гормонозаместительные составы и способы терапии

Country Status (11)

Country Link
EP (1) EP3548036A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020504093A (cg-RX-API-DMAC10.html)
KR (1) KR20200018383A (cg-RX-API-DMAC10.html)
CN (1) CN110290793A (cg-RX-API-DMAC10.html)
AU (1) AU2017394679A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019011655A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045024A1 (cg-RX-API-DMAC10.html)
IL (1) IL267023A (cg-RX-API-DMAC10.html)
MX (1) MX2019006513A (cg-RX-API-DMAC10.html)
RU (1) RU2019115913A (cg-RX-API-DMAC10.html)
WO (1) WO2018136161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AR100562A1 (es) * 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal

Also Published As

Publication number Publication date
IL267023A (en) 2019-07-31
AU2017394679A1 (en) 2019-06-13
WO2018136161A1 (en) 2018-07-26
WO2018136161A9 (en) 2019-08-22
EP3548036A4 (en) 2020-06-17
RU2019115913A3 (cg-RX-API-DMAC10.html) 2021-03-19
KR20200018383A (ko) 2020-02-19
MX2019006513A (es) 2019-08-14
JP2020504093A (ja) 2020-02-06
CN110290793A (zh) 2019-09-27
BR112019011655A2 (pt) 2019-10-22
EP3548036A1 (en) 2019-10-09
CA3045024A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
Vannuccini et al. Role of medical therapy in the management of uterine adenomyosis
Vestergaard et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure—a randomised controlled study
Mom et al. Hot flushes in breast cancer patients
Yi et al. Antidepressant-like behavioral, neurochemical and neuroendocrine effects of naringenin in the mouse repeated tail suspension test
JP2013508379A (ja) ネストロン（ｎｅｓｔｏｒｏｎｅ（登録商標））を使用する神経保護およびミエリン修復
NO20022292D0 (no) Nye topiske östradiolprogesteronpreparater med systemisk effekt
JP2010508275A (ja) 用量漸増長期サイクル治療プログラムを利用するホルモン処置の方法
Kim et al. Is complementary and alternative therapy effective for women in the climacteric period?
Poosari et al. Hormonal contraceptive use and breast cancer in Thai women
Egarter et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women
Zheng et al. Surgery-induced cryptorchidism induces apoptosis and autophagy of spermatogenic cells in mice
Deen Testosterone profiles and their correlation with sexual libido in male camels
Morales Recent findings on neuroprotection against excitotoxicity in the hippocampus of female rats
Mirkin et al. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms
FR2518879A1 (fr) Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
Hui et al. Preterm labour and birth: a survey of clinical practice regarding use of tocolytics, antenatal corticosteroids, and progesterone
CN102895524B (zh) 一种治疗妇科炎症的组合药物
Compton et al. Mood, cognition and Alzheimer's disease
Toole et al. Evaluation of irritation and sensitisation of two 50 μg/day oestrogen patches
Uygur et al. Effect on sexual life–a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate
JP2020504093A5 (cg-RX-API-DMAC10.html)
Cronje et al. Premenstrual syndrome and premenstrual dysphoric disorder
Biglia et al. Hormonal replacement therapy after gynaecological cancer
Ortiz-Pérez et al. An enriched environment and 17-beta estradiol produce similar pro-cognitive effects on ovariectomized rats
Rozenberg et al. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220405